A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® ...
Sprawdź aktualne oferty i ubiegaj się o pracę w spółkach Grupy Novartis na całym świecie. Business Data Analyst II Regular, Full time India Hyderabad (Office) Wrz 11, 2024 ...
Job Title Sort ascending Business Location Site Date Posted Product & Solutions Partner Oncology West (80-100%*) Regulär, Full time Innovative Medicines Switzerland Rotkreuz (Field-Based) Sep 16, 2024 ...
Job Title Sort ascending Business Location Site Date Posted 高级医药代表 Regulär (Außendienst), Full time Innovative Medicines China Guangzhou (Guangdong Province) Sep 19, 2024 Product & Solutions Partner ...
Job Title Sort ascending Business Location Site Date Posted 高级医药代表 Regulär (Außendienst), Full time Innovative Medicines China Guangzhou (Guangdong Province) Sep 19, 2024 Business Data Migration ...
Job Title Sort ascending Business Location Site Date Posted Tehnik (m/ž/d) Temporary (Fixed Term), Full time Innovative Medicines Slovenia Mengeš Sep 20, 2024 BPA Manager / Analyst CDI, Full time CTS ...